Respiratory syncytial virus

DOI Web Site PubMed PubMed PubMed 1 Citations 55 References Open Access

Bibliographic Information

Other Title
  • ＲＳウイルス（ｒｅｓｐｉｒａｔｏｒｙ　ｓｙｎｃｙｔｉａｌ　ｖｉｒｕｓ）

Search this article

Description

Human respiratory syncytial virus (RSV) is the most common worldwide cause of lower respiratory tract infections (LRI) in infants less than 6 months of age. The prophylaxis against RSV infection by vaccination has been unsuccessful because of its adverse effects. As antiviral drug, ribavirin spray (aerosol) had been used clinically and reduces the amount of virus load, without reducing the necessity of symptomatic therapy and the duration of hospitalization. Therefore RSV LRI has been treated mainly symptomatically. Recently humanized anti-RSV F protein monoclonal antibody was developed and prescribed for prevention in high-risk infants such as premature ones and those with chronic lung and congenital heart diseases. It reduced the incidence of hospitalization significantly. It has been introduced in clinical use in Japan following to Western countries. On the other hand, a number of anti-RSV drugs have now been investigation; however, no valuable drugs for clinical use have been yet developed.

Journal

  • Uirusu

    Uirusu 55 (1), 77-84, 2005

    The Japanese Society for Virology

Citations (1)*help

See more

References(55)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top